Aurinia Pharmaceuticals (AUPH) Earnings Date & Reports

Key Takeaways

• Aurinia reported third-quarter 2026 total revenue of $83.7 million, up 14% from $73.5 million a year earlier.
• LUPKYNIS net product sales reached $79.4 million, up 12% year over year and still the dominant revenue driver.
• Diluted earnings per share (EPS) came in at $0.23, roughly in line with consensus and flat versus the prior-year quarter.
• Net income was $31.7 million, essentially unchanged from $31.6 million in Q3 2025.
• The company raised its full-year 2026 total revenue guidance to $325 million–$330 million and narrowed net product sales guidance to $310 million–$315 million.
• Aurinia ended the quarter with $486.9 million in cash, cash equivalents, restricted cash and investments.
• For more detail on Aurinia's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies currently in focus.

Earnings Context and Why It Matters

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company whose lead product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for adults with active lupus nephritis (LN) — a serious kidney inflammation caused by the autoimmune disease lupus. Because LUPKYNIS generates the overwhelming majority of revenue, each quarterly report serves as a direct read on commercial execution, market share, and pricing. Q3 2026 also matters because it tests whether the company can sustain double-digit growth while advancing a broader pipeline. Investors closely track net product sales, profitability, cash generation, and management's guidance as key signals for the year ahead.

Reported Results

Aurinia reported total revenue of $83.7 million for the three months ended September 30, 2026, up 14% from $73.5 million in the prior-year period. Net product sales of LUPKYNIS were $79.4 million, up 12% from $70.6 million, while license, collaboration and royalty revenue from its partner Otsuka climbed 54% to $4.3 million.

Net income was $31.7 million, essentially flat versus $31.6 million a year earlier, and diluted EPS held steady at $0.23. For the nine months ended September 30, 2026, total revenue reached $244.6 million (up 19%), net income rose 35% to $103.5 million, and diluted EPS increased 38% to $0.76. The quarter was broadly in line with Wall Street expectations, with results landing near consensus rather than delivering a notable beat.

Management raised full-year 2026 total revenue guidance to $325 million–$330 million (from $315 million–$325 million) and narrowed net product sales guidance to $310 million–$315 million. The company closed the quarter with $486.9 million in cash, cash equivalents, restricted cash and investments.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. To explore these capabilities and apply them to your own watchlist, visit the AI Screener today.

Market Reaction and Investor Sentiment

Despite results that were largely in line with estimates and an upward revision to full-year guidance, Aurinia shares pulled back roughly 3% in the session following the October 30 release. The muted-to-negative reaction suggests investors were looking for a clearer beat or more aggressive pipeline catalysts, while lingering concerns around single-product concentration and competitive pressure from newer lupus nephritis therapies continue to weigh on sentiment. The pullback also reflects a market that has already priced in steady LUPKYNIS growth and is now focused on the durability of that growth beyond 2026.

Forward Outlook and Key Factors to Monitor

The raised full-year revenue guidance signals management's confidence in LUPKYNIS demand through year-end, but investors will be watching whether that momentum carries into 2027. The company narrowed its net product sales range to $310 million–$315 million, which implies continued sequential growth driven by patient expansion and adherence in the U.S. market.

On the pipeline front, Aurinia recently initiated PRESERVE, a Phase 4 study evaluating LUPKYNIS in combination with biologic agents such as belimumab, obinutuzumab, or anifrolumab in lupus nephritis. Positive data could strengthen LUPKYNIS's competitive positioning. Separately, the company is advancing aritinercept (AUR200), a dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), as a potential treatment for autoimmune diseases.

Key factors to monitor include the pace of LUPKYNIS prescription growth, Otsuka collaboration revenue, operating expense discipline, and any clinical readouts from the PRESERVE and aritinercept programs. Competition and patent-related dynamics — including the August 2026 settlement with Teva — also remain important considerations for the stock's longer-term trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations